Post Profile

U.S. agency says it advised Mylan that EpiPen was misclassified

WASHINGTON (Reuters) - A U.S. health agency said on Wednesday it had "expressly advised" Mylan that the company had misclassified the EpiPen in a way that led to the company paying a lower rebate to states.
read more


Related Posts

Mylan reiterates profit on EpiPen two-pack in U.S.

Health : Reuters: Health

(Reuters) - Under fire generic drugmaker Mylan NV reiterated it makes a net profit of $104, after taxes, for a pair of its EpiPen emergency allergy treatment sold in the United States, the company said in a filing on Monday.

Mylan shares languish at low valuation as EpiPen hearing nears

Health : Reuters: Health

NEW YORK (Reuters) - Shares of Mylan NV are trading at historically low valuations as the company's chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatmen...

Senate investigations panel to probe Mylan's EpiPen pricing

Health : Reuters: Health

WASHINGTON (Reuters) - The U.S. Senate's permanent subcommittee on investigations has decided to look into Mylan Pharmaceuticals' pricing of the EpiPen, according to a press release issued on Wednesday.

U.S. lawmakers question Mylan's Medicaid EpiPen rebates

Health : Reuters: Health

(Reuters) - Two key U.S. congressional committee members on Friday called for an investigation into whether Mylan NV, under fire for raising the price of its EpiPen device, overcharged the government's low-income healthcare program ...

Senators ask Justice Dept to consider probe of EpiPen Medicaid classification

Health : Reuters: Health

WASHINGTON (Reuters) - U.S. Senators Richard Blumenthal, Charles Grassley and Amy Klobuchar asked the Justice Department to investigate whether Mylan NV may have misclassified its EpiPen in order to pay lower rebates to the states.


Copyright © 2016 Regator, LLC